NASDAQ: ENSCEnsysce Biosciences Inc Stock
$0.58-0.05 (-7.94%)
Updated Apr 18, 2024
ENSC Price
$0.58
Fair Value Price
N/A
Market Cap
$4.25M
52 Week Low
$0.58
52 Week High
$7.20
P/E
-0.12x
P/B
-13.17x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-10.41
Operating Cash Flow
-$11M
Beta
0.41
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ENSC Overview
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENSC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENSC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ENSC due diligence checks available for Premium users.
Be the first to know about important ENSC news, forecast changes, insider trades & much more!
ENSC News
Valuation
ENSC fair value
Fair Value of ENSC stock based on Discounted Cash Flow (DCF)
Price
$0.58
Fair Value
$0.12
Overvalued by
388.33%
ENSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENSC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
15.68x
Market
41.33x
ENSC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-13.17x
Industry
5.76x
ENSC's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.5M
Profit Margin
0%
ENSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.7M
Liabilities
$3.4M
Debt to equity
-10.41
ENSC's short-term liabilities ($3.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENSC's short-term assets ($2.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENSC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$1.5M
ENSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENSC vs Biotech Stocks
Ensysce Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.